<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="221298">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202644</url>
  </required_header>
  <id_info>
    <org_study_id>SPD422-403</org_study_id>
    <secondary_id>2004-004061-15</secondary_id>
    <nct_id>NCT00202644</nct_id>
  </id_info>
  <brief_title>A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients</brief_title>
  <official_title>A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to
      be produced. Platelets are small cells carried around in the blood, which help form blood
      clots. When patients have too many platelets, there is a risk of blood clots forming
      unnecessarily and excessive bleeding. The aim of this study is to gain additional
      information on the safety profile of Anagrelide (Xagrid(r)) and Hydroxyurea (also known as
      hydroxycarbamide).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular safety as assessed by echocardiography over 3 years.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet counts during titration and long term</measure>
    <time_frame>3 &amp; 6 months and up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytoreductive impact on WBC and RBC lines</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of disease related thrombotic and haemorrhagic events</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Thrombocythemia, Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anagrelide</intervention_name>
    <description>Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of essential thrombocythaemia - high risk profile

          -  Previously untreated with a cytoreductive agent

          -  Females of childbearing potential must have a negative urine pregnancy test prior to
             entering the study and must agree to use effective birth control for the duration of
             the study

        Exclusion Criteria:

          -  Diagnosis of any other myeloproliferative disorder

          -  Any known cause for a secondary thrombocytosis

          -  Anti-coagulant and anti-aggregant therapies

          -  Known or suspected heart disease

          -  Left Ventricular Ejection Fraction &lt; 55%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirjana Gotic, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Haematology of Clinical Centre of Serbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment ''Dr Georgi Stranski'' - Pleven</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for active Treatment ''Alexandrovska'' Clinic of Haematology</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treament ''Sv. Marina'' - Varna Haematology Clinic</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers Services des Maladies du Sang</name>
      <address>
        <city>Angers</city>
        <state>Cedex 09</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis - Centre d'Investigation Clinique</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Medical and Health Science Centre</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar County Teaching Hospital</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pandy Kalman Hospital of Bekes County</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi Mor Teaching Hospital</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne Katedra i Klinika Hematologii i Transplantologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1</name>
      <address>
        <city>Lublin</city>
        <zip>21-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Onkologii i Chorob Wewnetrznych Akademii Medycznej</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Instytut Hematologii i Transfuzjologi</name>
      <address>
        <city>Warsaw</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitals da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-076</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Haematology of Clinical Centre of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Serbia</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 18, 2016</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Anagrelide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
